# Immuneering Corp: financial statements, quarterly

IMRX · Nasdaq · CIK 1790340 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/imrx.md) · [Financials](/companies/imrx/financials.md) · [Filings](/companies/imrx/filings.md) · [Insiders](/companies/imrx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/imrx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0 d](/filings/0001790340-24-000024.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Cost of revenue | $m | [0.0 d](/filings/0001790340-24-000024.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $m | [0.0 d](/filings/0001790340-24-000024.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [11.9 d](/filings/0001790340-25-000042.md) | [11.2](/filings/0001790340-25-000061.md) | [10.7](/filings/0001790340-25-000104.md) | [11.3](/filings/0001790340-25-000135.md) | [14.9 d](/filings/0001790340-26-000042.md) | [11.5](/filings/0001790340-26-000057.md) | [10.5](/filings/0001790340-26-000091.md) | [10.9](/filings/0001790340-26-000097.md) | [9.3 d](/filings/0001790340-26-000042.md) | [10.6](/filings/0001790340-26-000057.md) | [14.0](/filings/0001790340-26-000091.md) | [20.7](/filings/0001790340-26-000097.md) |
| Operating income | $m | [(16.3) d](/filings/0001790340-25-000042.md) | [(15.3)](/filings/0001790340-25-000061.md) | [(14.9)](/filings/0001790340-25-000104.md) | [(15.3)](/filings/0001790340-25-000135.md) | [(18.6) d](/filings/0001790340-26-000042.md) | [(15.5)](/filings/0001790340-26-000057.md) | [(14.8)](/filings/0001790340-26-000091.md) | [(15.4)](/filings/0001790340-26-000097.md) | [(13.8) d](/filings/0001790340-26-000042.md) | [(15.3)](/filings/0001790340-26-000057.md) | [(19.0)](/filings/0001790340-26-000091.md) | [(25.8)](/filings/0001790340-26-000097.md) |
| Net income | $m | [(15.1) d](/filings/0001790340-25-000042.md) | [(14.3)](/filings/0001790340-25-000135.md) | [(14.1)](/filings/0001790340-25-000135.md) | [(14.6)](/filings/0001790340-25-000135.md) | [(18.1) d](/filings/0001790340-26-000042.md) | [(15.0)](/filings/0001790340-26-000097.md) | [(14.4)](/filings/0001790340-26-000097.md) | [(15.0)](/filings/0001790340-26-000097.md) | [(11.6) d](/filings/0001790340-26-000042.md) | [(13.5)](/filings/0001790340-26-000097.md) | [(17.3)](/filings/0001790340-26-000097.md) | [(24.2)](/filings/0001790340-26-000097.md) |
| Diluted EPS | $ per share | not reported | [(0.49)](/filings/0001790340-25-000061.md) | [(0.47)](/filings/0001790340-25-000104.md) | [(0.49)](/filings/0001790340-25-000135.md) | not reported | [(0.42)](/filings/0001790340-26-000057.md) | [(0.40)](/filings/0001790340-26-000091.md) | [(0.38)](/filings/0001790340-26-000097.md) | not reported | [(0.21)](/filings/0001790340-26-000057.md) | [(0.27)](/filings/0001790340-26-000091.md) | [(0.37)](/filings/0001790340-26-000097.md) |
| Basic EPS | $ per share | not reported | [(0.49)](/filings/0001790340-25-000061.md) | [(0.47)](/filings/0001790340-25-000104.md) | [(0.49)](/filings/0001790340-25-000135.md) | not reported | [(0.42)](/filings/0001790340-26-000057.md) | [(0.40)](/filings/0001790340-26-000091.md) | [(0.38)](/filings/0001790340-26-000097.md) | not reported | [(0.21)](/filings/0001790340-26-000057.md) | [(0.27)](/filings/0001790340-26-000091.md) | [(0.37)](/filings/0001790340-26-000097.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [59.4](/filings/0001790340-25-000042.md) | [66.3](/filings/0001790340-24-000056.md) | [59.7](/filings/0001790340-24-000066.md) | [45.2](/filings/0001790340-24-000080.md) | [36.1](/filings/0001790340-26-000042.md) | [35.9](/filings/0001790340-25-000061.md) | [26.4](/filings/0001790340-25-000104.md) | [228](/filings/0001790340-25-000135.md) | [129](/filings/0001790340-26-000097.md) | [47.3](/filings/0001790340-26-000057.md) | [41.3](/filings/0001790340-26-000091.md) | [58.2](/filings/0001790340-26-000097.md) |
| Current assets | $m | [89.1](/filings/0001790340-25-000042.md) | [74.4](/filings/0001790340-24-000056.md) | [63.7](/filings/0001790340-24-000066.md) | [55.3](/filings/0001790340-24-000080.md) | [39.6](/filings/0001790340-26-000042.md) | [38.2](/filings/0001790340-25-000061.md) | [27.7](/filings/0001790340-25-000104.md) | [229](/filings/0001790340-25-000135.md) | [176](/filings/0001790340-26-000097.md) | [161](/filings/0001790340-26-000057.md) | [158](/filings/0001790340-26-000091.md) | [151](/filings/0001790340-26-000097.md) |
| Total assets | $m | [103](/filings/0001790340-25-000042.md) | [88.0](/filings/0001790340-24-000056.md) | [77.1](/filings/0001790340-24-000066.md) | [68.6](/filings/0001790340-24-000080.md) | [52.7](/filings/0001790340-26-000042.md) | [50.7](/filings/0001790340-25-000061.md) | [40.1](/filings/0001790340-25-000104.md) | [241](/filings/0001790340-25-000135.md) | [232](/filings/0001790340-26-000097.md) | [215](/filings/0001790340-26-000057.md) | [202](/filings/0001790340-26-000091.md) | [183](/filings/0001790340-26-000097.md) |
| Current liabilities | $m | [7.8](/filings/0001790340-25-000042.md) | [5.2](/filings/0001790340-24-000056.md) | [6.8](/filings/0001790340-24-000066.md) | [6.9](/filings/0001790340-24-000080.md) | [7.5](/filings/0001790340-26-000042.md) | [5.1](/filings/0001790340-25-000061.md) | [7.5](/filings/0001790340-25-000104.md) | [9.5](/filings/0001790340-25-000135.md) | [10.1](/filings/0001790340-26-000097.md) | [5.0](/filings/0001790340-26-000057.md) | [8.1](/filings/0001790340-26-000091.md) | [10.8](/filings/0001790340-26-000097.md) |
| Total liabilities | $m | [12.0](/filings/0001790340-25-000042.md) | [9.3](/filings/0001790340-24-000056.md) | [10.8](/filings/0001790340-24-000066.md) | [10.8](/filings/0001790340-24-000080.md) | [11.3](/filings/0001790340-26-000042.md) | [8.8](/filings/0001790340-25-000061.md) | [11.1](/filings/0001790340-25-000104.md) | [13.1](/filings/0001790340-25-000135.md) | [13.5](/filings/0001790340-26-000097.md) | [8.3](/filings/0001790340-26-000057.md) | [11.3](/filings/0001790340-26-000091.md) | [13.9](/filings/0001790340-26-000097.md) |
| Shareholders' equity | $m | [90.6](/filings/0001790340-26-000042.md) | [78.7](/filings/0001790340-25-000135.md) | [66.3](/filings/0001790340-25-000135.md) | [57.7](/filings/0001790340-25-000135.md) | [41.4](/filings/0001790340-26-000097.md) | [41.8](/filings/0001790340-26-000097.md) | [28.9](/filings/0001790340-26-000097.md) | [228](/filings/0001790340-26-000097.md) | [218](/filings/0001790340-26-000097.md) | [207](/filings/0001790340-26-000097.md) | [191](/filings/0001790340-26-000097.md) | [169](/filings/0001790340-26-000097.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(11.8) d](/filings/0001790340-25-000042.md) | [(15.5)](/filings/0001790340-25-000061.md) | [(11.5) d](/filings/0001790340-25-000104.md) | [(13.5) d](/filings/0001790340-25-000135.md) | [(14.5) d](/filings/0001790340-26-000042.md) | [(14.1)](/filings/0001790340-26-000057.md) | [(9.4) d](/filings/0001790340-26-000091.md) | [(12.0) d](/filings/0001790340-26-000097.md) | [(9.8) d](/filings/0001790340-26-000042.md) | [(18.4)](/filings/0001790340-26-000057.md) | [(16.5) d](/filings/0001790340-26-000091.md) | [(16.8) d](/filings/0001790340-26-000097.md) |
| Capital expenditure | $m | [0.2 d](/filings/0001790340-25-000042.md) | [0.0](/filings/0001790340-25-000061.md) | [0.0 d](/filings/0001790340-25-000104.md) | [0.0 d](/filings/0001790340-25-000135.md) | [0.0 d](/filings/0001790340-26-000042.md) | [0.0](/filings/0001790340-26-000057.md) | [0.0 d](/filings/0001790340-26-000091.md) | [0.0 d](/filings/0001790340-26-000097.md) | [0.1 d](/filings/0001790340-26-000042.md) | [0.1](/filings/0001790340-26-000057.md) | [0.0 d](/filings/0001790340-26-000091.md) | [0.0 d](/filings/0001790340-26-000097.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [26.4](/filings/0001790340-24-000056.md) | [28.6](/filings/0001790340-24-000066.md) | [29.3](/filings/0001790340-24-000080.md) | [29.4](/filings/0001790340-25-000061.md) | [29.7](/filings/0001790340-25-000104.md) | [29.8](/filings/0001790340-25-000135.md) | [35.5](/filings/0001790340-26-000057.md) | [36.0](/filings/0001790340-26-000091.md) | [39.7](/filings/0001790340-26-000097.md) | [64.7](/filings/0001790340-26-000057.md) | [64.7](/filings/0001790340-26-000091.md) | [64.7](/filings/0001790340-26-000097.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 25,938,064 at 2021-09-03, from the cover of the [10-Q filed 2021-09-09](/filings/0001558370-21-012336.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 18:24 ET. No prices; not investment advice.